- Il presente studio è un’analisi retrospettiva dei dati raccolti dall’Adelphi Paediatric Psoriasis Disease-Specific Programme cross-sectional survey.
- Una percentuale considerevole di pazienti ha presentato una malattia moderata o severa e sintomi persistenti relativi alla psoriasi, con coinvolgimento di multiple aree corporee.
- Una proporzione significativa di pazienti è stata sotto-trattata e ciò può spiegare l’alto impatto della malattia.
This study is a retrospective analysis using data collected from the Adelphi Paediatric Psoriasis Disease-Specific Programme cross-sectional survey.
Despite being treated for their psoriasis, a substantial proportion of paediatric patients presented with moderate (18.3%) or severe (1.3%) disease at sampling; 42.9% and 92.0% had a body surface area (BSA) of >10%, and 38.8% and 100.0% had a Psoriasis Area Severity Index (PASI) score >10, respectively. Overall, 69.9% of patients had only ever been treated with a topical therapy for their psoriasis. For patients with moderate or severe disease at sampling, 16.3% and 14.4% were currently receiving conventional systemics or biologic therapy, respectively.
There is a clinical unmet need in this paediatric population; a considerable percentage of patients still experienced moderate or severe disease and persistent psoriasis symptoms, with numerous body areas affected. A significant proportion of patients were undertreated, which may explain the high burden of disease observed.